Overview

Safety, Tolerability and Pharmacokinetics Study of CK-3773274

Status:
Completed
Trial end date:
2021-08-05
Target enrollment:
Participant gender:
Summary
The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.
Phase:
Phase 1
Details
Lead Sponsor:
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Collaborator:
Cytokinetics